Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent BSX Stock Price: $48.5
Summary: Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
John Aiken analyst at Barclays reiterates coverage on Boston Scientific (BSX) stock in the energy sector with a Buy rating and has set BSX's stock price target at $ 53.
TipRanks.com reports that Boston Scientific currently has 14 analysts offering 12-month price targets on BSX and the consensus is a Strong Buy rating with an average stock price target of $53.64. The most recent BSX stock price we have is $48.5 and we are not making any BSX forecasts at this time.
In addition, TradingView issued a Strong Buy rating for BSX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BSX. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BSX, please click here >>
Gilead Sciences, GILD
Recent GILD Stock Price: $84.5
Summary: Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Matthew Harrison analyst at Morgan Stanley reiterates coverage on Gilead Sciences (GILD) stock in the energy sector with a Hold rating and has set GILD's stock price target at $ 81.
TipRanks.com reports that Gilead Sciences currently has 19 analysts offering 12-month price targets on GILD and the consensus is a Moderate Buy rating with an average stock price target of $91.53. The most recent GILD stock price we have is $84.5 and we are not making any GILD forecasts at this time.
In addition, TradingView issued a Buy rating for GILD over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GILD. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on GILD, please click here >>
McKesson, MCK
Recent MCK Stock Price: $362.58
Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
George Hill analyst at Deutsche Bank reiterates coverage on McKesson (MCK) stock in the energy sector with a Buy rating and has set MCK's stock price target at $ 430.
TipRanks.com reports that McKesson currently has 11 analysts offering 12-month price targets on MCK and the consensus is a Strong Buy rating with an average stock price target of $428.91. The most recent MCK stock price we have is $362.58 and we are not making any MCK forecasts at this time.
In addition, TradingView issued a Sell rating for MCK over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MCK. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MCK, please click here >>
Eli Lilly & Co, LLY
Recent LLY Stock Price: $339.08
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Terence Flynn analyst at Morgan Stanley reiterates coverage on Eli Lilly & Co (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $ 455.
TipRanks.com reports that Eli Lilly & Co currently has 16 analysts offering 12-month price targets on LLY and the consensus is a Strong Buy rating with an average stock price target of $400.20. The most recent LLY stock price we have is $339.08 and we are not making any LLY forecasts at this time.
In addition, TradingView issued a Sell rating for LLY over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on LLY. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LLY, please click here >>
Humana, HUM
Recent HUM Stock Price: $476.57
Summary: Humana Inc. is a health care plan provider in the United States. The company provides health insurance benefits under Health Maintenance Organization, Private Fee-For-Service and Preferred Provider Organization plans. The company also provides other benefits with specialty products including dental, vision, and other supplementary benefits. Humana's medical and specialty insurance products allow members to access health care services primarily through its networks of health care providers. The company manages its business through the following segments: The Retail segment consists of Medicare benefits, which are marketed on a retail basis to individuals. The Group and Specialty segment comprises employer group commercial fully-insured medical and specialty health insurance benefits. The Healthcare Services - The segment consists of services offered to the company's health plan members as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs.
Scott Fidel analyst at Stephens reiterates coverage on Humana (HUM) stock in the energy sector with a Buy rating and has set HUM's stock price target at $ 590.
TipRanks.com reports that Humana currently has 14 analysts offering 12-month price targets on HUM and the consensus is a Strong Buy rating with an average stock price target of $619.86. The most recent HUM stock price we have is $476.57 and we are not making any HUM forecasts at this time.
In addition, TradingView issued a Strong Sell rating for HUM over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on HUM. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on HUM, please click here >>
Cardinal Health, CAH
Recent CAH Stock Price: $78.67
Summary: Cardinal Health Inc. is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company has two reporting segments: Pharmaceutical and Medical. The Pharmaceutical segment is the second largest pharmaceutical distributor in the United States and the largest nuclear pharmacy. Its products and services include pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services. The Medical segment manufactures products such as single-use surgical drapes, gowns and apparel; exam and surgical gloves; and fluid suction and collection systems and offers sterile and non-sterile procedure kits. These products are sold directly or distributed via third-party sources in the U.S., Canada, Europe, South America and the Asia/Pacific.'
Erin Wright analyst at Morgan Stanley reiterates coverage on Cardinal Health (CAH) stock in the energy sector with a Buy rating and has set CAH's stock price target at $ 90.
TipRanks.com reports that Cardinal Health currently has 9 analysts offering 12-month price targets on CAH and the consensus is a Moderate Buy rating with an average stock price target of $87.00. The most recent CAH stock price we have is $78.67 and we are not making any CAH forecasts at this time.
In addition, TradingView issued a Strong Buy rating for CAH over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CAH. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CAH, please click here >>
Siemens Healthineers AG, SEMHF
Recent SEMHF Stock Price: $52.996
Summary: N/A
Robert Davies analyst at Morgan Stanley reiterates coverage on Siemens Healthineers AG (SEMHF) stock in the energy sector with a Buy rating and has set SEMHF's stock price target at $ 63.18.
TipRanks.com reports that Siemens Healthineers AG currently has 11 analysts offering 12-month price targets on SEMHF and the consensus is a Strong Buy rating with an average stock price target of $64.59. The most recent SEMHF stock price we have is $52.996 and we are not making any SEMHF forecasts at this time.
In addition, TradingView issued a Strong Buy rating for SEMHF over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SEMHF. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SEMHF, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
